Efficacy and mechanism of the XPO1 inhibitor selinexor combined with decitabine in T-cell lymphoblastic lymphoma.

ABSTRACT:

Purpose

T-cell lymphoblastic lymphoma (T-LBL) has a poor response to traditional chemotherapy regimens, and is prone to relapse after treatment. Effective drugs are lacking for relapsed and refractory (RR) T-LBL patients, highlighting the need for novel treatments. Selinexor and decitabine have good effects on a variety of hematolymphatic diseases and solid tumors, but how effective they are in treating T-LBL has not been reported. In this study, we first investigated the efficacy and mechanism of selinexor combined with decitabine in the treatment of T- LBL.

Methods

The proliferation, apoptosis, and cell cycle progression of T-LBL cells were detected via CCK-8 and flow cytometry. Changes in mRNA expression and protein levels were assessed via mRNA sequencing, quantitative r

SUBMITTER: Meng M 

PROVIDER: S-EPMC12031777 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature